Contribution of Inhibitor of DNA Binding/Differentiation-3 and Endocrine Disrupting Chemicals to Pathophysiological Aspects of Chronic Disease

<table class="figure-group"><tr class="fig-image" id="a"><td><object data="https://static.hindawi.com/articles/bmri/volume-2017/6307109/figures/6307109.fig.003a.svgz" name="6307109.fig.003a" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(a) </b>Epigenetic mechanism of ID3 in neurological disorders. Summary of ID3 involvement in neurological disorders is presented</td></tr><tr class="fig-image" id="b"><td><object data="https://static.hindawi.com/articles/bmri/volume-2017/6307109/figures/6307109.fig.003b.svgz" name="6307109.fig.003b" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(b) </b>ID3 signaling pathway proposed in development of autism spectrum disorder</td></tr></table>

BioMed Research International

fig3

Figure 3

Figure 3: Contribution of Inhibitor of DNA Binding/Differentiation-3 and Endocrine Disrupting Chemicals to Pathophysiological Aspects of Chronic Disease 

Figure 3 | Contribution of Inhibitor of DNA Binding/Differentiation-3 and Endocrine Disrupting Chemicals to Pathophysiological Aspects of Chronic Disease 